--- title: "Drug Distributor 13Fs: McKesson, Cencora, Cardinal Health" type: learn slug: drug-distributor-13f-mck-cah-cor-decoder canonical_url: https://13finsight.com/learn/drug-distributor-13f-mck-cah-cor-decoder published_at: 2026-05-15T17:49:34.031Z updated_at: 2026-05-15T17:49:37.950Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 389 locale: en source: 13F Insight --- # Drug Distributor 13Fs: McKesson, Cencora, Cardinal Health > McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health anchor US pharmaceutical distribution 13F positioning. Specialty drug economics, GLP-1 distribution boom, generic deflation cycles, and capital-return discipline drive distinctive institutional patterns. US pharmaceutical distribution equities form a distinctive defensive-healthcare corner of institutional 13F positioning. McKesson, Cencora (COR, formerly AmerisourceBergen), and Cardinal Health anchor the three-company oligopoly. Specialty drug economics (high-margin biologics distribution), GLP-1 obesity therapy distribution boom, multi-year generic price deflation cycles, and disciplined capital-return frameworks drive distinctive institutional patterns. Reading drug distributor 13F positioning requires understanding the three-company oligopoly framework plus the multi-year specialty-and-GLP-1 cycle dynamics.The drug distribution business modelDrug distributors face four primary economic drivers:Three-company oligopoly. McKesson, Cencora, and Cardinal Health control approximately 90%+ of US pharmaceutical distribution. The oligopoly structure provides stable competitive dynamics plus disciplined capital allocation.Specialty drug economics. Specialty drug (biologics, oncology, orphan disease) distribution generates higher per-script revenue and margins than traditional generic distribution. Multi-year specialty mix expansion drives revenue trajectory.GLP-1 distribution boom. Multi-year GLP-1 obesity therapy (Ozempic, Wegovy, Mounjaro, Zepbound) distribution drives substantial revenue growth. Multi-year demand trajectory provides multi-year revenue tailwind.Generic deflation cycles. Multi-year generic drug price deflation cycles compress per-script economics on traditional generic distribution. Cycle inflections affect operator margins.Major US drug distributorsMcKesson (MCK)Largest US pharmaceutical distributor. Diversified across pharmaceutical distribution, medical-surgical solutions, prescription technology solutions, and international operations. Multi-decade dividend growth track record.Cencora (COR)Formerly AmerisourceBergen, rebranded 2023. Diversified pharmaceutical distribution plus specialty plus animal health (MWI Veterinary Supply) plus international operations. Multi-year capital deployment plus shareholder returns.Cardinal Health (CAH)Diversified pharmaceutical distribution plus medical solutions plus pharmaceutical and specialty services. Multi-year operational restructuring plus capital return discipline.How institutional managers position around drug distributorsThree patterns:Pattern 1: Oligopoly-stability concentrationMCK-concentrated active manager positions reflect three-company oligopoly stability plus disciplined operational management.Pattern 2: GLP-1 boom positioningAll three distributors benefit from GLP-1 distribution boom. Concentrated active manager positions reflect multi-year GLP-1 demand thesis.Pattern 3: Specialty growth positioningCOR-concentrated active manager positions reflect specialty drug distribution thesis plus animal health diversification.How to read drug distributor 13F positioningThree rules:Rule 1: Identify specialty mix exposureEach distributor's specialty drug mix determines margin profile.Rule 2: Watch GLP-1 distribution disclosureQuarterly GLP-1-related revenue plus broader specialty disclosure drives multi-quarter visibility.Rule 3: Cross-check generic deflation cycleMulti-year generic price deflation cycles affect traditional generic distribution economics.What drug distributor positioning signalsOligopoly-stability conviction. Concentrated MCK positions signal manager view on oligopoly competitive dynamics.GLP-1 boom conviction. Concentrated positions across MCK, COR, CAH signal GLP-1 distribution demand thesis.Specialty growth conviction. Concentrated COR positions signal specialty drug distribution thesis.For real-time tracking of drug distributor 13F activity, see the institutional signals feed. ## FAQ ### What are the major US drug distributors? Three major US pharmaceutical distributors forming an oligopoly: (1) McKesson (MCK) — largest with diversified pharma, medical-surgical, technology, international; (2) Cencora (COR, formerly AmerisourceBergen rebranded 2023) — pharma plus specialty plus animal health (MWI); (3) Cardinal Health (CAH) — distribution plus medical solutions plus specialty services. The three control approximately 90%+ of US distribution. ### How does the three-company oligopoly work? McKesson, Cencora, and Cardinal Health control approximately 90%+ of US pharmaceutical distribution. The oligopoly structure provides stable competitive dynamics — capital-intensive distribution infrastructure plus established manufacturer relationships create barriers to entry. The three companies maintain disciplined capital allocation including buybacks plus consistent dividend growth. Reading positions across all three reveals oligopoly-stability thesis. ### What is specialty drug distribution? Specialty drug distribution covers biologics, oncology, orphan disease, and other high-cost therapies typically requiring temperature-controlled handling and specialized dispensing. Specialty distribution generates higher per-script revenue and margins than traditional generic distribution. Multi-year specialty mix expansion across the cohort drives revenue trajectory. Cencora's MWI Veterinary Supply plus US Oncology Network strengthen specialty positioning. ### How does GLP-1 affect drug distributors? GLP-1 receptor agonist therapies (Eli Lilly's Mounjaro/Zepbound, Novo Nordisk's Ozempic/Wegovy) drive substantial multi-year distribution revenue. The drugs are high-priced ($800-1,500+ monthly) and require regular distribution to pharmacies and patients. Multi-year demand trajectory plus expanding indications (cardiovascular, kidney, liver) provide multi-year revenue tailwind for all three distributors. Reading GLP-1 disclosure reveals long-cycle revenue impact. ### How does generic deflation affect distribution margins? Multi-year generic drug price deflation cycles compress per-script economics on traditional generic distribution. Generic price deflation typically runs 5-10% annually. Distributors offset deflation through volume growth plus specialty mix expansion plus operational efficiency. Reading per-script revenue trends versus volume trends reveals deflation impact. Cycle inflections (when deflation slows or reverses) affect operator margins. ### Why is McKesson a dividend-aristocrat? McKesson has increased dividends for 15+ consecutive years with substantial buyback programs supplementing dividend growth. The largest US drug distribution franchise generates substantial free cash flow supporting consistent capital return. Multi-decade competitive position in three-company oligopoly plus disciplined capital allocation produces capital-return durability. P&C insurance balance sheet positions plus dividend-focused active managers concentrate MCK reflecting allocation. --- Source: 13F Insight — https://13finsight.com/learn/drug-distributor-13f-mck-cah-cor-decoder Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-15T17:49:37.950Z